Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cantor Fitzgerald
UBS
Argus Health
Queensland Health
Dow
Chinese Patent Office
Johnson and Johnson
Fuji

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLEEVEC

« Back to Dashboard

Clinical Trials for Gleevec

Trial ID Title Status Sponsor Phase Summary
NCT00022737 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
NCT00025246 Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
NCT00027586 Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
NCT00027586 Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed M.D. Anderson Cancer Center Phase 2 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gleevec

Condition Name

Condition Name for Gleevec
Intervention Trials
Leukemia 27
Chronic Myelogenous Leukemia 13
Chronic Myeloid Leukemia 12
Sarcoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gleevec
Intervention Trials
Leukemia 83
Leukemia, Myeloid 68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 66
Leukemia, Myeloid, Chronic-Phase 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gleevec

Trials by Country

Trials by Country for Gleevec
Location Trials
United States 437
Canada 37
China 30
Australia 26
United Kingdom 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gleevec
Location Trials
Texas 50
California 29
Pennsylvania 28
New York 27
Illinois 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gleevec

Clinical Trial Phase

Clinical Trial Phase for Gleevec
Clinical Trial Phase Trials
Phase 4 2
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 108
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gleevec
Clinical Trial Phase Trials
Completed 117
Terminated 23
Active, not recruiting 15
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gleevec

Sponsor Name

Sponsor Name for Gleevec
Sponsor Trials
National Cancer Institute (NCI) 49
Novartis 32
M.D. Anderson Cancer Center 29
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gleevec
Sponsor Trials
Other 167
Industry 106
NIH 53
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Fuji
Teva
Baxter
Chubb
McKesson
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.